G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer solutions that are not physically sound. Subscribe to our newsletter for the latest ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

Overview AI is speeding up drug discovery by analyzing large biological and chemical data in a short time.Deep learning and AI systems help design new drug mole ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

Researchers from David Baker's lab (University of Washington) have designed this antibody from scratch to neutralize a deadly toxin from C. difficile. [Ian Haydon] “Life could not exist without ...

PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design today announced collaboration agreement in AI for new drug design with Chiesi Group, the ...

This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...

This study addresses endosomal escape in oligonucleotide therapies and how engineered peptides can enhance intracellular drug delivery efficiency.

Ola Engkvist is the Executive Director and Head of Molecular AI in Discovery Sciences within R&D at AstraZeneca (headquartered in Cambridge, UK). His team harnesses advanced computational technologies ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...